FierceMedTech opens nominations for the 2019 Fierce 15

FierceMedTech Fierce 15

Our 2018 picks for the FierceMedTech Fierce 15 showcased the innovative companies we believe can make strong, tangible impacts—not just by moving their individual needles past the limits of today’s medical technology, but by chasing breakthroughs that could move the field forward as a whole.

They included tech-powered upgrades of decades-old devices and techniques, where injuries, failures and mortality rates had stagnated. Some companies developed new methods to query the body itself, diving into its cells and proteins to provide more precise pictures of disease. Others zoomed outwards, using digital biomarkers and therapeutics to capture vast streams of data and sift them for ways toward better health, both mental and physical.

Now, we’re asking for your help in finding the next class of Fierce 15, so we can keep spotlighting the work of the most promising startups in the industry. Nominations are open for private companies from all over the world, and those at different levels of development.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Please enter their names and the reasons you think they’re fierce in the form below—by Monday, Dec. 16. The full list of last year’s Fierce 15 is available here.

 

Read more on

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.